{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:43:18Z","timestamp":1792795398941,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jcf.2025.10.001","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T08:31:53Z","timestamp":1761121913000},"page":"1149-1155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The treatment with Elexacaftor\/Tezacaftor\/Ivacaftor significantly increases serum bilirubin and decreases blood platelets in children and adolescents with cystic fibrosis homozygous or double heterozygous for the F508del CFTR variant"],"prefix":"10.1016","volume":"24","author":[{"given":"Alice","family":"Castaldo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Cimbalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3642-8928","authenticated-orcid":false,"given":"Cristina","family":"Fevola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Raia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1106-4424","authenticated-orcid":false,"given":"Vito","family":"Terlizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1500-0746","authenticated-orcid":false,"given":"Monica","family":"Gelzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Sepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Tosco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2025.10.001_bib0001","doi-asserted-by":"crossref","DOI":"10.1177\/17534666251323194","article-title":"Cystic fibrosis: new challenges and perspectives beyond elexacaftor\/tezacaftor\/ivacaftor","volume":"19","author":"Terlizzi","year":"2025","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.jcf.2025.10.001_bib0002","article-title":"Update on advances in cystic fibrosis towards a cure and implications for primary care clinicians","volume":"54","author":"Terlizzi","year":"2024","journal-title":"Curr Probl Pediatr Adolesc Health Care"},{"key":"10.1016\/j.jcf.2025.10.001_bib0003","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241210358","article-title":"Theratyping of the rare CFTR genotype A559T in rectal organoids and nasal cells reveals a relevant response to Elexacaftor (VX-445) and Tezacaftor (VX-661) combination","volume":"24","author":"Kleinfelder","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcf.2025.10.001_bib0004","doi-asserted-by":"crossref","first-page":"207","DOI":"10.14639\/0392-100X-1328","article-title":"An \"ex vivo model\" contributing to the diagnosis and evaluation of new drugs in cystic fibrosis","volume":"37","author":"Di Lullo","year":"2017","journal-title":"Acta Otorhinolaryngol Ital"},{"key":"10.1016\/j.jcf.2025.10.001_bib0005","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/humu.23741","article-title":"Two CFTR variants within codon 970 differently impact on the chloride channel functionality","volume":"40","author":"Amato","year":"2019","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jcf.2025.10.001_bib0006","doi-asserted-by":"crossref","first-page":"e1656","DOI":"10.1002\/mgg3.1656","article-title":"Ex vivo model predicted in vivo efficacy of CFTR modulator therapy in a child with rare genotype","volume":"9","author":"Terlizzi","year":"2021","journal-title":"Mol Genet Genomic Med"},{"key":"10.1016\/j.jcf.2025.10.001_bib0007","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00110-2023","article-title":"Theratyping cystic fibrosis patients to guide elexacaftor\/tezacaftor\/ivacaftor out-of-label prescription","volume":"62","author":"Dreano","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2025.10.001_bib0008","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1091\/mbc.e14-04-0935","article-title":"From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations","volume":"27","author":"Veit","year":"2016","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.jcf.2025.10.001_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2022.102239","article-title":"Current state of CFTR modulators for treatment of cystic fibrosis","volume":"65","author":"Despotes","year":"2022","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.jcf.2025.10.001_bib0010","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3390\/ph16030410","article-title":"Elexacaftor-Tezacaftor-Ivacaftor: a life-changing triple combination of CFTR modulator drugs for Cystic Fibrosis","volume":"16","author":"Bacalhau","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jcf.2025.10.001_bib0011","first-page":"70","article-title":"Impact of highly effective modulator therapy on gastrointestinal symptoms and features in people with cystic fibrosis","volume":"54","author":"Cecchetti","year":"2025","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.jcf.2025.10.001_bib0012","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1164\/rccm.202201-0219OC","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor therapy on lung clearance index and magnetic resonance imaging in patients with cystic fibrosis and one or two F508del alleles","volume":"206","author":"Graeber","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2025.10.001_bib0013","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1016\/j.jcf.2021.11.006","article-title":"Magnetic resonance imaging of cystic fibrosis: multi-organ imaging in the age of CFTR modulator therapies","volume":"21","author":"McBennett","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.10.001_bib0014","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.jcf.2023.01.004","article-title":"Improved glucose tolerance after initiation of Elexacaftor \/Tezacaftor \/ Ivacaftor in adults with cystic fibrosis","volume":"22","author":"Steinack","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.10.001_bib0015","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del variant: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2025.10.001_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2025.108221","article-title":"Real-world effectiveness and safety of elexacaftor\/tezacaftor\/ivacaftor in cystic fibrosis patients with Phe508del -gating and -residual function genotypes","volume":"245","author":"Salvatore","year":"2025","journal-title":"Respir Med"},{"key":"10.1016\/j.jcf.2025.10.001_bib0017","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2025.10.001_bib0018","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.202502-0512OC","article-title":"Long-term safety and efficacy of Elexacaftor\/Tezacaftor\/Ivacaftor in children \u22656 years with cystic fibrosis and at least one F508del Allele: a 192-week, phase 3, open-label extension study","author":"Wainwright","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2025.10.001_bib0019","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A phase 3 open-label study of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2025.10.001_bib0020","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1164\/rccm.202202-0392OC","article-title":"Efficacy and safety of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis heterozygous for F508del and a minimal function mutation: a phase 3b, randomized, placebo-controlled study","volume":"206","author":"Mall","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2025.10.001_bib0021","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1002\/ppul.27125","article-title":"Effectiveness and safety of elexacaftor\/tezacaftor\/ivacaftor in children aged 6-11 years with cystic fibrosis in a real-world setting","volume":"59","author":"Dacc\u00f2","year":"2024","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2025.10.001_bib0022","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1164\/rccm.202301-0084OC","article-title":"Phase 3 open label clinical trial of elexacaftor\/tezacaftor\/ivacaftor in children aged 2-5 years with cystic fibrosis and at least one F508del allele","volume":"208","author":"Goralski","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2025.10.001_bib0023","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1016\/j.jcf.2021.07.001","article-title":"Karnsakul W.Drug-induced liver injury from elexacaftor\/ivacaftor\/tezacaftor","volume":"21","author":"Lowry","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.10.001_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2024.114176","article-title":"Reported adverse events in a multicenter cohort of patients ages 6-18 years with cystic fibrosis and at least one F508del allele receiving elexacaftor\/tezacaftor\/ivacaftor","volume":"274","author":"Terlizzi","year":"2024","journal-title":"J Pediatr"},{"key":"10.1016\/j.jcf.2025.10.001_bib0025","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-12333-8","article-title":"Blood platelet reduction after elexacaftor\/tezacaftor\/ivacaftor treatment in people with cystic fibrosis may depend on systemic inflammation reduction","volume":"15","author":"Castaldo","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcf.2025.10.001_bib0026","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.jcf.2023.06.013","article-title":"Hyperbilirubinemia and Gilbert's syndrome in Cystic Fibrosis patients treated with elexacaftor\/tezacaftor\/ivacaftor","volume":"22","author":"Terlizzi","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.10.001_bib0027","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.japh.2023.02.015","article-title":"Incidence of transaminitis in adults with cystic fibrosis taking elexacaftor\/tezacaftor\/ivacaftor","volume":"63","author":"Wood","year":"2023","journal-title":"J Am Pharm Assoc"},{"key":"10.1016\/j.jcf.2025.10.001_bib0028","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jcf.2023.01.007","article-title":"Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on liver tests at a large single adult cystic fibrosis centre","volume":"22","author":"Tewkesbury","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.10.001_bib0029","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1327958","article-title":"One year of treatment with elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis homozygous for the F508del variant causes a significant increase in liver biochemical indexes","volume":"10","author":"Castaldo","year":"2024","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.jcf.2025.10.001_bib0030","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-68511-7","article-title":"Liver biochemical indexes and cholesterol metabolism in cystic fibrosis patients with F508del\/CFTR variant genotype after elexacaftor\/tezacaftor\/Ivacaftor treatment","volume":"14","author":"Castaldo","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcf.2025.10.001_bib0031","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1097\/HEP.0000000000000646","article-title":"Cystic fibrosis screening, evaluation and management of hepatobiliary disease consensus recommendations","volume":"79","author":"Sellers","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.jcf.2025.10.001_bib0032","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.jcf.2023.09.009","article-title":"Standards for the care of people with CF","volume":"22","author":"Southern","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.10.001_bib0033","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1515\/cclm-2017-0553","article-title":"Multicenter validation study for the certification of a CFTR gene scanning method using next generation sequencing technology","volume":"56","author":"Bergougnoux","year":"2018","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.jcf.2025.10.001_bib0034","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1183\/09031936.00080312","article-title":"ERS global lung function initiative. Multi-ethnic reference values for spirometry for the 3\u201395 year age range: the global lung function 2012 equations","volume":"40","author":"Quanjer","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2025.10.001_bib0035","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1136\/gut.39.4.580","article-title":"Faecal elastase 1: a novel, highly sensitive, and specific tubeless pancreatic function test","volume":"39","author":"Loser","year":"1996","journal-title":"Gut"},{"key":"10.1016\/j.jcf.2025.10.001_bib0036","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/MPG.0b013e31820b0227","article-title":"Comparison of fecal elastase-1 and pancreatic function testing in children","volume":"54","author":"Wali","year":"2012","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jcf.2025.10.001_bib0037","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1111\/crj.12796","article-title":"Supervised physical exercise improves clinical, anthropometric and biochemical parameters in adult cystic fibrosis patients: a 2-year evaluation","volume":"12","author":"Elce","year":"2018","journal-title":"Clin Respir J"},{"key":"10.1016\/j.jcf.2025.10.001_bib0038","series-title":"Il test del sudore raccomandazioni per una corretta esecuzione ed interpretazione dei risultati","year":"2023"},{"key":"10.1016\/j.jcf.2025.10.001_bib0039","unstructured":"CDC. National Center for Health Statistics, https:\/\/www.cdc.gov\/growthcharts\/index.htm; 2024 [accessed 10 November 2024]."},{"key":"10.1016\/j.jcf.2025.10.001_bib0040","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1164\/rccm.201908-1590ST","article-title":"Standardization of Spirometry 2019 update. An official American Thoracic Society and European Respiratory Society technical statement","volume":"200","author":"Graham","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2025.10.001_bib0041","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1164\/rccm.202008-3176LE","article-title":"Safety and efficacy of Elexacaftor\/Tezacaftor\/Ivacaftor for 24 weeks or longer in people with Cystic Fibrosis and one or more F508del alleles: interim results of an open-label phase 3 clinical trial","volume":"203","author":"Griese","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2025.10.001_bib0042","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jcf.2023.03.002","article-title":"Real-world safety and effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: interim results of a long-term registry-based study","volume":"22","author":"Bower","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.10.001_bib0043","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02029-2022","article-title":"VX17-445-105 Study Group. Long-term safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study","volume":"62","author":"Daines","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2025.10.001_bib0044","first-page":"307","article-title":"Case series: hyperbilirubinemia under elexacaftor\/tezacaftor\/ivacaftor in the presence of Gilbert\u2019s syndrome","volume":"24","author":"Weitzel","year":"2024","journal-title":"Pulmon Med"},{"key":"10.1016\/j.jcf.2025.10.001_bib0045","series-title":"Nephrology and hepatology","article-title":"End stage liver disease","author":"Beath","year":"2016"},{"key":"10.1016\/j.jcf.2025.10.001_bib0046","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1515\/cclm-2015-1151","article-title":"Reduced absorption and enhanced synthesis of cholesterol in patients with cystic fibrosis: a preliminary study of plasma sterols","volume":"54","author":"Gelzo","year":"2016","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.jcf.2025.10.001_bib0047","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1515\/cclm-2019-1112","article-title":"Influence of pancreatic status on circulating plasma sterols in patients with cystic fibrosis","volume":"58","author":"Gelzo","year":"2020","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.jcf.2025.10.001_bib0048","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.abb.2011.08.012","article-title":"Molecular pathways for intracellular cholesterol accumulation: common pathogenic mechanisms in Niemann-Pick disease type C and cystic fibrosis","volume":"515","author":"Cianciola","year":"2011","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.jcf.2025.10.001_bib0049","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1242\/jcs.03350","article-title":"Misassembled mutant DeltaF508 CFTR in the distal secretory pathway alters cellular lipid trafficking","volume":"120","author":"Gentzsch","year":"2007","journal-title":"J Cell Sci"},{"key":"10.1016\/j.jcf.2025.10.001_bib0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0245302","article-title":"Impaired cholesterol metabolism in the mouse model of cystic fibrosis. A preliminary study","volume":"16","author":"Amato","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.jcf.2025.10.001_bib0051","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.4049\/jimmunol.1900899","article-title":"Platelets in inflammation and resolution","volume":"203","author":"Margraf","year":"2019","journal-title":"J Immunol"},{"key":"10.1016\/j.jcf.2025.10.001_bib0052","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jcf.2024.12.010","article-title":"Effect of elexacaftor-tezacaftor-ivacaftor on liver transient elastography, fibrosis indices and blood tests in children with cystic fibrosis","volume":"24","author":"Terlizzi","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.10.001_bib0053","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jcf.2023.09.006","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor on liver fibrosis markers in adults with cystic fibrosis","volume":"23","author":"Tewkesbury","year":"2024","journal-title":"J Cyst Fibros"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325024853?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325024853?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T07:34:19Z","timestamp":1779953659000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199325024853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1569199325024853"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2025.10.001","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The treatment with Elexacaftor\/Tezacaftor\/Ivacaftor significantly increases serum bilirubin and decreases blood platelets in children and adolescents with cystic fibrosis homozygous or double heterozygous for the F508del CFTR variant","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2025.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}